Home » Market News » DirectorsTalk Highlights » Peanut Allergy advances stir excitement
Allergy therapeutics plc

Peanut Allergy advances stir excitement

For people with peanut allergies, placing a carefree order at a bakery or candy shop may remain a pipe dream for now. But surviving an accidental exposure without emergency medical treatment is looking more likely as research on new preventive treatments forges ahead.

Training the immune system to accept small doses of the allergen such that accidents don’t have to trigger fear and emergency measures is the focus of a growing number of clinical trials and biopharmaceutical interest, experts said.

Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.